BioInvent International
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Camino Announces C$5.6 Million Investment with Strategic Investors12.11.2025 12:00:00 CET | Press release
Not for distribution to United States newswire services or for release publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. VANCOUVER, BC / ACCESS Newswire / November 12, 2025 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise total gross proceeds of approx. C$5.6 Million (the "Financing"). The Financing will consist of the issuance of 15,554,666 common shares of the Company (each a "Share") at a price per Share of C$0.36. Participants in the financing will include two significant new shareholders, EMX Royalty Corp. ("EMX") and Continental General Insurance Company ("CGIC"). Based in Austin, Texas, CGIC is one of the largest shareholders of Camino's partner, Nittetsu Mining. CGIC is a life and health insurance company founded in 1961, and is an active investor in producing and development-stage mining asse
Xsens Announces New Xsens Link for Motion Capture Across Humanoid Robotics, Health, Sports, and Entertainment12.11.2025 10:00:00 CET | Press release
Next-Generation motion capture from Xsens combines smarter sensors, seamless connectivity, and adaptive design to deliver precise, real-world motion data. ENSCHEDE, NL / ACCESS Newswire / November 12, 2025 / Xsens, a Movella brand and world leader in inertial motion capture technology, today announced the launch of the next-generation Xsens Link, an all-new motion capture system that redefines accuracy, usability, and versatility for users across industries. Redesigned from the ground up, the new Xsens Link delivers superior comfort, smarter data output, and minimal maintenance, empowering users to capture motion data with unprecedented speed and fidelity - whether in a robotics lab, film studio, or on the training field. "We've taken everything our customers love about Xsens and built the next generation around comfort, consistency, and flexibility," says Dennis Kloppenburg, product manager at Xsens. "From animators to athletes to robotics developers and researchers, The new Link deli
Air T Welcomes Creditor Support for Rex Acquisition11.11.2025 23:00:00 CET | Press release
MINNEAPOLIS, MINNESOTA / ACCESS Newswire / November 11, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce that a majority of Rex's creditors-both in number and in value-have voted in favor of our bid to acquire Rex at the second meeting of creditors held on 11 November 2025. This strong endorsement reflects confidence in our vision for Rex and our commitment to regional aviation in Australia. We take our responsibilities under the proposed Deed of Company Arrangement seriously. We understand the Administrators intend to close the transaction by year-end, and we are working closely with all parties to ensure a smooth and timely completion. Air T is grateful for the support shown throughout this process and looks forward to finalizing the acquisition and beginning a new chapter for Rex and regional communities across Australia. NOTE REGARDING STAKEHOLDER QUESTIONS If you have questions related to this release or other Air T matters, please use our interactive Q&A capability, throug
MicroVision Announces Third Quarter 2025 Results11.11.2025 22:05:00 CET | Press release
REDMOND, WASHINGTON / ACCESS Newswire / November 11, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its third quarter 2025 results. Key Business and Operational Highlights Appointed 30-year industry veteran Glen DeVos as Chief Executive Officer, elevating automotive capabilities. Introduced next generation solid-state lidar sensor, MOVIA S, offering an energy-efficient and cost-effective short-range solution for a wide variety of automotive, industrial, and defense sector applications. Launched industry-disrupting Tri-Lidar Architecture solution, offering an alternative to the lidar industry's myopic focus on single sensor solutions. Executed agreement to acquire Scantinel Photonics, a German developer of long-range FMCW lidar, joining investment and strategic partners in advancing lidar-on-chip solution for commercial vehicle and passenger car markets. Established design office and testing
Climate Goals Threatened by Industrialised Animal Farming, Reveals Key International Study11.11.2025 15:20:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 11, 2025 / A new study in Animals highlights that industrialized animal farming is one of the most powerful - yet persistently neglected - forces driving the climate and biodiversity crises. The analysis, "The Missing Target: Why Industrialized Animal Farming Must Be at the Core of the Climate Agenda," synthesizes evidence from 47 international studies and concludes that reducing livestock production and embracing plant-based food systems is essential for meeting global climate goals. Major Insights Across global research, livestock farming contributes an estimated 12-20% of all greenhouse gas emissions annually, with the most comprehensive studies yielding the highest figures. The most modern accounting methods, which include the impacts of deforestation, bottom trawling and cooling effects from certain atmospheric pollutants, reveal that 52% of present-day global warming is attributable to animal agriculture. Animal agriculture occupies over 80
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom